AC
VNDA icon

Ascend Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Ascend Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-249,596
Closed -$2.32M – 149
2015
Q4 		$2.32M Buy
+249,596
New +$2.49M 0.08% 127
2015
Q2 		– Sell
-168,300
Closed -$1.57M – 198
2015
Q1 		$1.57M Buy
+168,300
New +$1.9M 0.05% 144

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital's VNDA Position: Q1 2016 in Review

Ascend Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2016, closing a stake of 249,596 shares — an estimated $2.32M sold.

Ascend Capital first reported a position in VNDA in Q1 2015 and held it in 2 quarters. The position peaked at $2.32M in Q4 2015. 116 funds tracked by Wall St. Rank hold VNDA as of Q1 2016.

  • Ascend Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Ascend Capital sold 249,596 Vanda Pharmaceuticals shares in Q1 2016, an estimated $2.32M.
  • Ascend Capital first reported a position in Vanda Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Ascend Capital's Vanda Pharmaceuticals position peaked at $2.32M in Q4 2015.
  • 116 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2016.

Based on Ascend Capital's 13F filing for Q1 2016, filed 13 May 2016.